Literature DB >> 12145687

SHP-1 expression in peripheral T cells from patients with Sezary syndrome and in the T cell line HUT-78: implications in JAK3-mediated signaling.

F León1, C Cespón, A Franco, M Lombardía, E Roldán, L Escribano, A Harto, P González-Porqué, G Roy.   

Abstract

SHP-1 is a key tyrosine phosphatase that acts as a negative regulator of signal transduction in lymphocytes, which has been found down-regulated in several T cell lines derived from human T cell malignancies. The standardization of a sensitive ELISA for the quantification of SHP-1 protein in peripheral T and B lymphocytes has enabled us to quantify the SHP-1 content of freshly isolated T cells from patients with Sezary syndrome and in the Sezary T cell line HUT-78. In all cases, a dramatic decrease in the content of this protein, when compared with the content in healthy volunteer controls, was observed. These results were corroborated when the expression of SHP-1 mRNA was analyzed. In order to study whether there was any correlation between SHP-1 protein expression and tyrosine phosphorylated state of JAK3, the state of phosphorylation of JAK3 was studied in the T cell line HUT-78, and found to be highly phosphorylated. These results suggest that SHP-1 might be involved in maintaining the IL-2R/JAK3 signaling pathway under control and point towards a role of SHP-1 in the pathogenesis of the disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12145687     DOI: 10.1038/sj.leu.2402546

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

Review 1.  Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas.

Authors:  Tracey J Mitchell; Susan John
Journal:  Immunology       Date:  2005-03       Impact factor: 7.397

2.  Alteration in the gene encoding protein tyrosine phosphatase nonreceptor type 6 (PTPN6/SHP1) may contribute to neutrophilic dermatoses.

Authors:  Andrew B Nesterovitch; Zsuzsa Gyorfy; Mark D Hoffman; Ellen C Moore; Nada Elbuluk; Beata Tryniszewska; Tibor A Rauch; Melinda Simon; Sewon Kang; Gary J Fisher; Katalin Mikecz; Michael D Tharp; Tibor T Glant
Journal:  Am J Pathol       Date:  2011-03-04       Impact factor: 4.307

3.  Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma.

Authors:  Lise M Lindahl; Andreas Willerslev-Olsen; Lise M R Gjerdrum; Pia R Nielsen; Edda Blümel; Anne H Rittig; Pamela Celis; Bjorn Herpers; Jürgen C Becker; Birgitte Stausbøl-Grøn; Mariusz A Wasik; Maria Gluud; Simon Fredholm; Terkild B Buus; Claus Johansen; Claudia Nastasi; Lukas Peiffer; Linda Kubat; Michael Bzorek; Jens O Eriksen; Thorbjørn Krejsgaard; Charlotte M Bonefeld; Carsten Geisler; Tomas Mustelin; Erik Langhoff; Michael Givskov; Anders Woetmann; Mogens Kilian; Thomas Litman; Lars Iversen; Niels Odum
Journal:  Blood       Date:  2019-07-22       Impact factor: 22.113

4.  SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients.

Authors:  George P Christophi; Chad A Hudson; Ross C Gruber; Christoforos P Christophi; Cornelia Mihai; Luis J Mejico; Burk Jubelt; Paul T Massa
Journal:  Lab Invest       Date:  2008-01-21       Impact factor: 5.662

5.  Mechanisms of SHP-1 P2 promoter regulation in hematopoietic cells and its silencing in HTLV-1-transformed T cells.

Authors:  Koichi Nakase; Jihua Cheng; Quan Zhu; Wayne A Marasco
Journal:  J Leukoc Biol       Date:  2008-11-12       Impact factor: 4.962

6.  Interferon-beta treatment in multiple sclerosis attenuates inflammatory gene expression through inducible activity of the phosphatase SHP-1.

Authors:  George P Christophi; Michael Panos; Chad A Hudson; Chriso Tsikkou; Cornelia Mihai; Luis J Mejico; Burk Jubelt; Paul T Massa
Journal:  Clin Immunol       Date:  2009-06-25       Impact factor: 3.969

7.  Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma.

Authors:  Ji-Lin Chen; Pei-Yi Chu; Chun-Teng Huang; Tzu-Ting Huang; Wan-Lun Wang; Yu-Hsuan Lee; Yuan-Ya Chang; Ming-Shen Dai; Chung-Wai Shiau; Chun-Yu Liu
Journal:  Mol Med       Date:  2022-08-08       Impact factor: 6.376

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.